- Home
- CWAN vs LEGN Comparison
CWAN vs LEGN Comparison
Compare CWAN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CWAN | LEGN |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 5.9B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CWAN | LEGN |
|---|---|---|
| Price | $23.21 | $17.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | $25.09 | ★ $63.08 |
| AVG Volume (30 Days) | ★ 4.3M | 1.5M |
| Earning Date | 04-29-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $731,368,000.00 | N/A |
| Revenue This Year | $31.67 | $46.27 |
| Revenue Next Year | $18.27 | $28.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 61.88 | N/A |
| 52 Week Low | $15.74 | $16.24 |
| 52 Week High | $27.76 | $45.30 |
Technical Indicators
Market Signals| Indicator | CWAN | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.41 | 37.53 |
| Support Level | $23.15 | $16.24 |
| Resistance Level | $23.61 | $20.39 |
| Average True Range (ATR) | 0.20 | 0.78 |
| MACD | 0.00 | -0.17 |
| Stochastic Oscillator | 22.69 | 3.64 |
Price Performance
Historical ComparisonAbout CWAN Clearwater Analytics Holdings Inc.
Clearwater Analytics describes its mission as aiming to be the world's most trusted and comprehensive technology platform for the entire investment cycle. Clearwater has historically focused on back-office functions such as investment accounting, but with acquisitions such Enfusion, Beacon, and Bistro, the firm has broadened its focus with front-office and middle-office capabilities. Clearwater primarily serves insurance companies, asset managers, hedge funds, and corporate treasuries. Pro forma for Enfusion, about 76% of Clearwater's revenue is generated in the US.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.